Breaking News Instant updates and real-time market news.

JAZZ

Jazz Pharmaceuticals

$108.04

-2.94 (-2.65%)

16:06
11/28/16
11/28
16:06
11/28/16
16:06

Jazz Pharmaceuticals: Patient enrollment complete for Phase 3 study of JZP-110

Jazz Pharmaceuticals announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness associated with narcolepsy. "This is an important milestone in our JZP-110 Phase 3 program," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer of Jazz Pharmaceuticals. "We expect to report the top-line results from our two Phase 3 studies evaluating ES in obstructive sleep apnea in the first quarter of 2017 and the top-line results from this Phase 3 narcolepsy study in the second quarter of 2017."

  • 29

    Nov

  • 03

    Dec

  • 14

    Dec

JAZZ Jazz Pharmaceuticals
$108.04

-2.94 (-2.65%)

10/05/16
BMOC
10/05/16
NO CHANGE
Target $195
BMOC
Outperform
Jazz Pharmaceuticals risk/reward favorable, says BMO Capital
BMO Capital analyst Gary Nachman said recent Jazz Pharmaceutical management meetings confirm his positive thesis and said risk/reward in shares is favorable at current levels. Nachman said management sounded very confident in the company's outlook and he remains optimistic that a favorable Xyrem settlement would lift a significant overhang on the stock and help unlock untapped value with the pipeline. The analyst reiterates his Outperform rating and $195 price target on shares.
10/28/16
LEER
10/28/16
NO CHANGE
Target $178
LEER
Outperform
Jazz Pharmaceuticals price target lowered to $178 from $202 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $178 from $202 on valuation. However, the analyst continues to recommend investors buy Jazz Pharmaceuticals' shares given the "strong" 2017 catalyst outlook, including a likely continuation of Xyrem patent settlements, favorable Phase 3 data for JZP-110 for excessive daytime sleepiness and approval of Vyxeos for secondary Acute Myeloid Leukemia. Gerberry reiterates an Outperform rating on the shares.
11/09/16
UBSW
11/09/16
NO CHANGE
Target $168
UBSW
Buy
Jazz Pharmaceuticals well positioned for 2017, says UBS
UBS analyst Marc Goodman said he likes Jazz Pharmaceuticals' setup for 2017, noting its easier comps, the potential settlement of its Xyrem patent trial, data expected from its pipeline, and expectations for approval of its Vyxeos drug candidate. Goodman reiterated his Buy rating and $168 price target on Jazz Pharmaceuticals shares following the company's Q3 report.
11/09/16
LEER
11/09/16
NO CHANGE
Target $182
LEER
Outperform
Jazz Pharmaceuticals price target raised to $182 from $178 at Leerink
Leerink analyst Jason Gerberry raised his price target for Jazz Pharmaceuticals to $182 from $178 as he sees the 2017 setup as favorable with likely Xyrem legal patent settlements, abating investor concerns around governmental scrutiny over historical Xyrem price increases, JZP-110 Phase 3 data and a likely approval for Vyxeos in secondary Acute Myeloid Leukemia. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

PG

Procter & Gamble

$92.64

-1.76 (-1.86%)

06:04
09/22/17
09/22
06:04
09/22/17
06:04
Hot Stocks
Trian identifies numerous errors in recent Procter & Gamble presentation »

Trian Fund, whose…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHUBA

CommerceHub

$23.42

-0.06 (-0.26%)

06:04
09/22/17
09/22
06:04
09/22/17
06:04
Initiation
CommerceHub initiated  »

CommerceHub initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

EVLV

Evine Live

$1.03

0.01 (0.98%)

06:02
09/22/17
09/22
06:02
09/22/17
06:02
Initiation
Evine Live initiated  »

Evine Live initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Sep

  • 16

    Nov

AMZN

Amazon.com

$964.65

-8.56 (-0.88%)

06:01
09/22/17
09/22
06:01
09/22/17
06:01
Hot Stocks
Amazon to add 359,000 square foot office in New York City »

Governor Andrew M. Cuomo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

ICPT

Intercept

$73.70

-24.42 (-24.89%)

06:01
09/22/17
09/22
06:01
09/22/17
06:01
Downgrade
Intercept rating change  »

Wells yesterday…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$171.11

-1.06 (-0.62%)

05:55
09/22/17
09/22
05:55
09/22/17
05:55
Hot Stocks
Instagram adds Face Filters to live video, to roll out globally »

Instagram says in a blog…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

PSTG

Pure Storage

$15.02

0.19 (1.28%)

05:55
09/22/17
09/22
05:55
09/22/17
05:55
Recommendations
Pure Storage analyst commentary  »

Pure Storage price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

AABA

Altaba

$66.59

-0.33 (-0.49%)

, BABA

Alibaba

$177.39

-0.56 (-0.31%)

05:52
09/22/17
09/22
05:52
09/22/17
05:52
Recommendations
Altaba, Alibaba, Yahoo Japan analyst commentary  »

Altaba price target…

AABA

Altaba

$66.59

-0.33 (-0.49%)

BABA

Alibaba

$177.39

-0.56 (-0.31%)

YAHOY

Yahoo Japan

$8.90

-0.08 (-0.89%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

REPYY

Repsol

$18.47

0.1 (0.54%)

05:52
09/22/17
09/22
05:52
09/22/17
05:52
Upgrade
Repsol rating change  »

Repsol upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

05:49
09/22/17
09/22
05:49
09/22/17
05:49
Downgrade
Versartis rating change  »

Versartis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRPIF

BRP Inc.

05:48
09/22/17
09/22
05:48
09/22/17
05:48
Upgrade
BRP Inc. rating change  »

BRP Inc. upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PG

Procter & Gamble

$92.64

-1.76 (-1.86%)

05:47
09/22/17
09/22
05:47
09/22/17
05:47
Hot Stocks
Glass Lewis recommends Procter & Gamble holders vote for Nelson Peltz »

Trian Fund Management,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDXG

MiMedx

$12.27

-0.07 (-0.57%)

05:46
09/22/17
09/22
05:46
09/22/17
05:46
Recommendations
MiMedx analyst commentary  »

MiMedx shares offer…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

BA

Boeing

$256.04

0.58 (0.23%)

05:45
09/22/17
09/22
05:45
09/22/17
05:45
Hot Stocks
Boeing sees growing demand for new airplanes in Southeast Asia »

Boeing projects a demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

05:45
09/22/17
09/22
05:45
09/22/17
05:45
General news
Breaking General news story  »

San Francisco Federal…

SSNI

Silver Spring

$16.15

0.01 (0.06%)

, ITRI

Itron

$75.85

-0.4 (-0.52%)

05:40
09/22/17
09/22
05:40
09/22/17
05:40
Downgrade
Silver Spring, Itron rating change  »

Silver Spring downgraded…

SSNI

Silver Spring

$16.15

0.01 (0.06%)

ITRI

Itron

$75.85

-0.4 (-0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JUNO

Juno Therapeutics

$41.62

-3.59 (-7.94%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Syndicate
Juno Therapeutics 6.1M share Secondary priced at $41.00 »

Morgan Stanley and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

  • 22

    Sep

AA

Alcoa

$46.25

-1.25 (-2.63%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOBE

Bob Evans

$77.29

-0.2 (-0.26%)

, POST

Post Holdings

$86.97

-0.39 (-0.45%)

05:38
09/22/17
09/22
05:38
09/22/17
05:38
Downgrade
Bob Evans, Post Holdings rating change  »

Bob Evans downgraded to…

BOBE

Bob Evans

$77.29

-0.2 (-0.26%)

POST

Post Holdings

$86.97

-0.39 (-0.45%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$153.39

-2.68 (-1.72%)

05:36
09/22/17
09/22
05:36
09/22/17
05:36
Recommendations
Apple analyst commentary  »

Piper ups Apple target to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

TIF

Tiffany

$89.85

-0.08 (-0.09%)

05:31
09/22/17
09/22
05:31
09/22/17
05:31
Downgrade
Tiffany rating change  »

Tiffany downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 04

    Oct

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

05:27
09/22/17
09/22
05:27
09/22/17
05:27
Recommendations
Ascendis Pharma, Versartis analyst commentary  »

Versartis failure bodes…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BDX

Becton Dickinson

$191.56

-2.44 (-1.26%)

, BCR

C.R. Bard

$317.37

-1.19 (-0.37%)

05:20
09/22/17
09/22
05:20
09/22/17
05:20
Initiation
Becton Dickinson, C.R. Bard initiated  »

Becton Dickinson…

BDX

Becton Dickinson

$191.56

-2.44 (-1.26%)

BCR

C.R. Bard

$317.37

-1.19 (-0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MB

Mindbody

$24.85

0.05 (0.20%)

05:16
09/22/17
09/22
05:16
09/22/17
05:16
Upgrade
Mindbody rating change  »

Mindbody upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GPN

Global Payments

$96.34

0.72 (0.75%)

05:14
09/22/17
09/22
05:14
09/22/17
05:14
Initiation
Global Payments initiated  »

Global Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.